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Abstract
It has recently been recognised that vaccine adjuvants play a critical role in directing the nature of a vaccine induced
effector response. In the present study, several adjuvants were evaluated for their ability to protect sheep after field
vaccination with the larval-specific Haemonchus contortus antigen, HcsL3. Using a suboptimal antigen dose, aluminium
adjuvant was shown to reduce the cumulative faecal egg counts (cFEC) and worm burden by 23% and 25% respectively, in
agreement with a previous study. The addition of Quil A to the aluminium-adjuvanted vaccine brought cFEC back to control
levels. Vaccination with the adjuvant DEAE-dextran almost doubled the protection compared to the aluminium-adjuvanted
vaccine resulting in 40% and 41% reduction in cFEC and worm counts compared to controls. Examination of skin responses
following i.d. injection of exsheathed L3, revealed that cFEC was negatively correlated with wheal size and tissue eosinophils
for the DEAE-dextran and aluminium-adjuvanted groups respectively. These studies have for the first time shown the
potential of DEAE-dextran adjuvant for helminth vaccines, and discovered significant cellular correlates of vaccine-induced
protection.
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Introduction
The generation of natural immunity against gastrointestinal
nematode (GIN) parasites, and helminth parasites in general,
displays some unique characteristics compared to viral and
bacterial infections, in particular in the recruitment and activation
of ‘allergic’ or type-2 effector cells (mast cells and eosinophils)
[1,2,3]. Attempts to generate subunit vaccines against GIN
parasites have in the past relied heavily on successes achieved
with microbial vaccines, including the use of potent vaccine
adjuvants that generate high antibody responses, the major
correlates of protection in most existing vaccines [4]. While
helminth vaccines based on the ‘hidden antigen’ approach i.e. not
boosted by natural immunity, may also rely on high antibody titres
[5], it is likely that vaccination strategies aimed at mimicking and
accelerating natural immunity will require the induction of both
cellular and humoral immunity including the induction of a type-2
effector response.
Vaccine adjuvants have received increased attention in recent
years with the realisation that they are the main drivers of both the
magnitude and type of adaptive response generated after
vaccination [6,7]. For helminth vaccines aimed at replicating
natural immunity, a type-2 immune response may be essential to
achieve protection. Indeed, in a previous small pen trial, we
observed that immunization with a purified, larval-specific surface
antigen of H. contortus, was only protective when administered with
the type-2 adjuvants, aluminium hydroxide and cholera toxin,
while addition of pertussis toxin increased antibody titres but
abrogated protection [8].
In the present study, we performed a more extensive trial using
3 different adjuvants currently in use in veterinary vaccines, and
determined both the levels of protection and the immune response
generated. In order to be compatible with farm management
practices, vaccinations were performed on pasture using only two
subcutaneous immunizations. A preliminary dose-response trial
established significant high levels (61–69%) of protection with the
largest antigen dose and a significant but lower 27% protection in
the second highest dose group using aluminium hydroxide as the
adjuvant [9]. To assess the capacity of different adjuvants to
improve protection and conserve antigen, the second highest
antigen dose was used in the present study. The results of the study
established that one rarely used adjuvant improved protection over
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aluminium adjuvant, while another more widely used type-1
adjuvant abrogated protection.
Assessment of vaccine efficacy based on infection trials is costly
and labour intensive and the availability of more amenable
immune correlates of protection is desirable for the development
and validation of most vaccines [10]. Antibody levels are at present
the only known correlates of vaccine-induced immunity, however
no correlation with antibodies and protection has been observed
with the current larval-specific vaccine [8,9]. In the present study,
we also examined different immune parameters after vaccination
and discovered significant immune correlates of protection in the
two vaccinated groups of sheep that showed reduced egg counts
and worm burdens.
Materials and Methods
Preparation and formulation of the vaccine
A surface extract was prepared from exsheathed L3 as described
previously [9]. Briefly, L3 were exsheathed with CO2, resus-
pended in PBS and placed in a boiling water bath for 15 min.
Larvae were pelleted by centrifugation and the supernatant,
containing the surface extract, was depleted of small MW
molecules and concentrated in one step using 50 kD cut-off
Centricon Centrifugal Filter Units (Millipore). This resulted in one
dominant, typically broad 75–90 kD band on PAGE, weakly
staining with coomassie but reacting strongly with the HcsL3-
specific mAb Hc22. As the antigen stained very poorly with
coomassie (and not at all with silver stain) accurate weight
estimation was not possible and vaccine doses were therefore
expressed as L3-equivalents. Each antigen vaccinated sheep
received an antigen dose extracted from 20,000 L3 equivalents,
a suboptimal dose previously resulting in a small but still significant
27% reduction in cumulative faecal egg count (cFEC) using the
adjuvant aluminium hydroxide [9].
Immunization setup is summarised in Table 1. Three groups of
10 sheep each were vaccinated with antigen added to aluminium
adjuvant with (Group 2) or without (Group 4) addition of Quil A
(Brenntag Nordic, Frederikssund, Denmark), or with antigen
added to DEAE-dextran adjuvant (DD) (Sigma-Aldrich) (group 3).
A separate group of sheep (Group 1, control) received the
aluminium adjuvant without antigen. As preliminary in vitro
experiments (not shown) established strongest binding of the
antigen to aluminium phosphate (AlPO4), this preparation was
chosen instead of the aluminium hydroxide used in previous
experiments [8,9], and prepared in house by mixing 4.73 mL of
35% w/v AlCl3 with 17.04 mL of 25% w/v Na3PO4.12H20 and
0.47 mL of 30% w/v NaOH, adjusted to final volume with water.
The aluminium phosphate was adjusted to a concentration of
1 mg/ml aluminium with sterile PBS (pH 7.2) in the final
vaccination dose and mixed thoroughly with (Groups 2 &4) or
without (control Group1) the antigen on an automated rotator for
1 h at room temperature (25uC). Quil A (2 mg/ml) was adjusted to
a concentration of 1 mg/ml with sterile PBS (pH 7.2) in the final
vaccination dose and added to the antigen/AlPO4 preparation
before mixing (Group 2). DEAE-dextran (DD) (20%w/v; pH 6.8)
was adjusted to a concentration of 100 mg/ml with sterile PBS
(pH 7.2) in the final vaccination dose and mixed thoroughly with
the antigen as described above. Each vaccine dose was contained
in 1 ml solution. Enough vaccine was prepared for 2 immuniza-
tion doses, and the second dose was stored at 4uC until used.
Experimental animals, immunization and challenge
protocol
Merino-cross wethers were raised and maintained on pasture at
a Woodend farm (Northern Victoria). At 8 months of age (week -
14), forty sheep were selected and treated with a long-acting
anthelmintic, CydectinH, to remove any existing parasites. Only
low egg counts were detected throughout the grazing period
(,100 eggs per gram) and no egg counts were detected after
treatment. At week -8, sheep were randomised and allocated to 4
experimental groups (n = 10) based on stratified body weight
ranking, bled for pre-vaccination serum and given their first
immunization dose by subcutaneous injection in the neck region.
Four weeks later (week – 4), they were given their second
immunization and bled one week later (week -3) for the post-
vaccination serum. Two weeks after the second immunization
(week -2), they were transported and housed in a large indoor shed
at the Monash University experimental Werribee farm. After two
weeks acclimatization (week 0), they were infected twice with 7000
L3 on day 0 and day +3 using the H. contortus strain, Haecon-5.
This strain was isolated in 2006 from the field by Novartis Animal
Health, and shown to be more pathogenic than the previously
used laboratory strains. Two sheep died on pasture and one
indoors due to causes unrelated to the trial.
Parasitological, serological and haematological
measurements
Faecal egg counts (FEC) were assessed between 21 to 56 days
post infection (dpi) according to the modified McMaster method
and expressed as eggs per gram (EPG) faeces. Egg counts were
determined for each collection day, and mean cumulative faecal
egg counts (cFEC) were calculated by adding all EPG values for
each sheep over the whole collection period. Worm burdens were
collected from Groups 1, 3 and 4 and worm recovery was
performed as described previously [9]. Briefly, the stomach
(abomasum) was removed and cut along the greater curvature.
Abomasal contents and washings were collected and made up to a
volume of 2 L with tap water containing 1% formalin. The
solution was vigorously bubbled with air and 10% transferred to
glass trays for manual counting of parasites.
Serum samples were collected before vaccination (week -8), one
week after the second immunization (week -3), before challenge
(week 0) and one week after challenge (week +1). For determining
packed cell volume (PCV), blood was collected before (day 0) and
1, 4 and 7 weeks after challenge in 10 ml EDTA tubes and spun in
a Haematocrit centrifuge.
Serum anti-HcsL3 antibodies were determined by enzyme
linked immunosorbant assay (ELISA) as described previously
[8,9]. Briefly, ELISA plates (Nunc, Denmark) were coated
overnight with L3 surface extract in 100 ml carbonate buffer
pH 9.6 and incubated with various dilutions of sheep sera. Specific
antibody isotype responses were determined by incubating with
mAbs against ovine IgG1, IgG2 [11] and IgA (Serotec, Bicester,
UK) followed by HRP-conjugated rabbit anti-mouse reagent
(DAKO, Denmark) and developed with 39, 39, 59, 59- tetramethyl-
benzidine dihydrochloride hydrate (TMB; Invitrogen, VIC,
Australia). Antigen-specific IgE was determined by ELISA of
ammonium sulphate-treated serum samples as described previ-
ously [12]. Antibody levels were also compared to a separate
control group of 8 sheep that had been kept in indoor pens, worm
free for 2–3 months (Penned group).
Worm Vaccination with Different Adjuvants
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Intradermal injections and skin responses
Two days before kill, cutaneous hypersensitivity reactions were
performed by two intradermal injections of 100 H. contortus
exsheathed L3 in 100 ml saline in the right inside back leg of the
animal. Two injections of saline were administered as a control at
two adjacent sites. The skin temperature and wheal size were
measured at 2 hours post injection and at 48 hrs, just prior to
euthanasia. Skin temperature at the injection site was recorded
with a digital infra-red temperature gauge (Kelly supply company,
Australia) and wheal size was measured with digital calipers. After
gross removal of the injected skin area, a hollow punch was used to
cut skin samples of approximately 1 cm2 in size which was
sufficient to remove the majority of the inflamed tissue surround-
ing the injection site, and this was divided in 2 equal parts for
histology and future RNA extraction. Histology samples were
placed in 10% neutral buffered formalin and then embedded in
paraffin, sectioned and stained with haematoxylin and eosin by the
Monash University Histology Laboratory. Eosinophils in the
entire biopsy sections were counted and expressed as the mean
number of cells per 1 mm2 tissue (+/- SEM).
Ethics Statement
Handling of animals and experimental procedures were
approved by the Monash University Animal Ethics Committee
(Ethics # SOBSA/P/2009/44).
Statistical Analysis
Data were analysed using GraphPad Prism5. Each vaccinated
group was compared against the adjuvant control group using
Student’s t-test with significance set at p,0.05. Values were log
transformed before analysis if variations were significantly
different. One way ANOVA was used to compare values between
all groups. The Spearman’s rank correlation coefficient was
calculated to determine significant dependence between two
variables.
Results
Protection levels after challenge infection of sheep 
Eggs per gram faeces (EPG) and cumulative faecal egg counts
(cFEC) were reduced in group 4, immunized with antigen and
aluminium adjuvant, compared to the control group 1 (Fig.1A&B).
The degree of protection (23%, Table 1) was similar to that
observed previously with this antigen dose (27%, [9]), although
levels were not significant in this case. Addition of Quil A to the
same vaccine (group 2) increased egg counts to control levels
(Fig.1A&B). Group 3 which received DD as the adjuvant showed
the best protection, which was almost double that of group 4 (40%)
and reached significance compared to the control group 1
(Table 1). To ensure that the increased protection in group 3
was not due to the DD adjuvant only, in a separate infection trial
(not shown) a group of 10 sheep injected with DD alone were
compared with a non-injected control group; no difference was
observed in the cFEC of these groups, with cFEC of 23893 (SEM
67628) and 23420 (SEM 66693), respectively.
Post-mortem worm counts were performed on the control group
1 and the two vaccinated groups 3 and 4 (Fig. 1C). Mean worm
counts in group 3 were significantly reduced compared to the
control group (p = 0.008). Individual worm counts in group 4
showed wide segregation, indicative of responder and non-
responder sheep resulting in no significant difference of the mean
compared to group 1. Protection levels for worm counts were
similar to the cFEC at 41% and 25% for groups 3 and group 4,
respectively (Table 1).
All groups showed a decrease in PCV values after infection but
the mean PCV values at the end of the experiment were similar in
groups 3 and 4 and, although not significant, higher than those in
groups 1 and 2 (Fig. 2).
Antibody responses during vaccination and challenge
As observed previously [9], antibody levels overall were elevated
in pasture reared sheep compared to penned sheep even before the
start of vaccination, and levels decreased in the control and most
vaccinated groups when transferred to indoor pens (Fig. 3). Only
the DD group showed significantly increased antibody levels 1
week after the second vaccination compared to the unvaccinated
control group for the IgG2 and IgE isotypes (Fig. 3). No increase in
antibody levels was detectable after the challenge infection.
Skin responses after intradermal injection of saline or L3
larvae
Skin temperatures at 2 h were consistently lower in the L3
compared to the saline injected sites (Fig.4A), and this was
significant for the two aluminium adjuvant-vaccinated groups
(Groups 2 and 4).
Wheal sizes were elevated in all groups at 2 h with no significant
difference between groups (Fig.4B). Wheal sizes had decreased
significantly by 48 hrs in groups 1, 2 and 4 but remained at a
higher level in group 2 compared to group 4. Group 3 showed
only a small decrease in wheal size from 2 to 48 h, and its 48 h
wheal size was significantly higher than groups 1 and 4.
There was no difference in eosinophil counts between the
control and vaccinated groups in biopsies taken 48 h after saline
injection, with a combined mean of 2169.3 eos/mm2. After
injection of L3, skin eosinophil counts increased in all groups
compared to the saline injections (Fig.4C). This was most
Table 1. Sheep numbers, immunization protocols and levels of protection against H.contortus infection.
Group # Sheep numbers (n) Adjuvant
Antigen (HcsL3) L3
equivalents
cFEC; % protection
relative to control
Mean worm burdens; %
protection relative to
control
1 (Control) 10 AlPO4 0 - -
2 10 AlPO4 + Quil A 20 K 3 ND
3 10 DEAE-dextran(DD) 20 K 40* 41**
4 10 AlPO4 20 K 23 25
ND: not done; *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0078357.t001
Worm Vaccination with Different Adjuvants
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vaccinated with HcsL3 administered with different 
adjuvants.
pronounced in the DD group 3, where numerous eosinophils were
present, often aggregated in large granulomas (Fig. 5) which were
not included in the counts. One sheep in the aluminium adjuvant
vaccinated group 4 showed a much higher eosinophil count
(29696801) then the other sheep in this group, and with this
outlier excluded, mean eosinophil counts in group 4 were
significantly below the control group 1 (Fig. 4C).
Correlations between protection, antibody levels and
skin responses
The Spearman’s rank correlation coefficients were calculated
for all parasitological and immunological measurements, and
correlations that showed significance detailed in Table 2. cFEC
were significantly correlated with worm counts across all groups
examined, and negatively correlated with PCV values. There was
no significant correlation between cFEC and any of the antibody
isotype levels, except for a slight negative correlation with IgE
when all groups were combined. There were however significant
but distinct correlations between skin responses and cFEC in the
two vaccinated groups with lowest egg counts, groups 3 and 4.
Group 3 showed a highly significant negative correlation of cFEC
with the 2 h wheal response, while cFEC in group 4 were highly
positively correlated with changes in skin temperature at 2 h and
negatively correlated with eosinophil counts 48 h after i.d.
injection of L3 larvae. The vaccinated group 2 (AlPO4+Quil A)
also showed a lower but significant negative correlation between
cFEC and L3 eosinophil counts.
IgG2, but not IgE, correlated significantly with wheal size at 2 h
Figure 1. Faecal egg counts and worm burden after challenge
of vaccinated sheep. A: Mean (+SEM) daily eggs/gram faeces (EPG); B:
Mean (+SEM) cumulative faecal egg count (FEC); C: individual and mean
(+/2SEM) total worm counts. For details of experimental groups, refer
to Table 1. Significantly different from the control group at p,0.05 (*)
or p,0.01 (**).
doi:10.1371/journal.pone.0078357.g001
Figure 2. Packed cell volume (PCV) of peripheral blood after
challenge of vaccinated sheep. Mean (+SEM) PCV of groups at 49
days post infection (DPI). The mean PCV of all sheep before infection
(day 0) was 34.2 (SD 2.3). For details of experimental groups, refer to
Table 1.
doi:10.1371/journal.pone.0078357.g002
Worm Vaccination with Different Adjuvants
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in group 3 and when all groups were combined. At 48 h, this
correlation was lost and replaced by significant correlations with
IgE and IgG1, again only in group 3 or when all groups were
combined.
Discussion
Recent advances in innate immunity have revealed the critical
role adjuvants and vaccine delivery systems play in directing the
strength and nature of a vaccine response [6,7]. In particular,
innate receptors, including Toll-like receptors (TLRs) have
received wide attention as potential new targets for incorporation
into vaccine formulations [13]. However, in most cases of
currently used adjuvant systems, the exact innate stimulation
pathways are unknown and may not involve TLR activation [6].
This is the case for the most commonly used aluminium adjuvants
[14], as well as the two other adjuvants used in the present study,
DEAE-dextran (DD) and Quil A. As adjuvants may act differently
in different species [15], it is critical to test each experimental
vaccine with different adjuvants in the target species.
Vaccination in the current study was performed with a larval-
specific antigen and the protective effect is therefore likely to
manifest against the early L3 stage during the first 1–2 days after
infection, before it moults to an L4. The local response to
challenge infections in the gastrointestinal tract is however difficult
to study without sacrificing the animals. An attempt was therefore
made to replicate the vaccine-induced response against L3 larvae
by intradermal injections of exsheathed L3 and subsequent
examination of the injection sites. This was done after establish-
ment of the challenge infection so as not to compromise the
vaccine efficacy study. Inflammation is generally associated with
an increase in temperature and it was therefore surprising that
temperature measurements at the L3 injected sites were consis-
tently lower than in the saline injected sites, and this difference was
significant in the two groups vaccinated with aluminium adjuvant.
This may be related to the findings that type-2 immune responses
Figure 3. Serum antibody responses after challenge of vaccinated sheep.Mean antibody isotype responses of sheep before vaccination (wk
-8), 1 week after vaccination (wk -3), at day of challenge (wk 0) and 1 week after challenge (wk +1). Serum diluted 1/5000 (IgG1), 1/500 (IgG2), 1/20
(IgA) or 1/32 ammonium sulphate cut (IgE). For details of experimental groups, refer to Table 1. Dashed line represents the mean of a separate group
of 8 sheep kept in indoor pens for 2–3 months. *Significant difference between group 3 and control group 1.
doi:10.1371/journal.pone.0078357.g003
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induced by helminth extracts or aluminium adjuvants dampen
type-1 immune responses and pro-inflammatory cytokines [16,17].
Aluminium adjuvants have been used in most vaccines since the
early 1900 and have a proven immune boosting and safety record
[6,14]. The exact action of aluminium adjuvant has not been
completely elucidated but seems to be associated with its unique
interaction with dendritic cells both in vitro [18] and in vivo [19].
Aluminium adjuvants are known to bias the immune response
towards a type-2 phenotype, including the recruitment of eosino-
phils, which is generally not considered favourable for bacterial or
viral vaccines [14,17]. However, for protection against helminth
parasites, a type-2 response may be advantageous, as eosinophil
killing of helminth larvae is a prominent feature of natural immunity
in these infections [20]. In particular, eosinophil-mediated killing of
Figure 4. Skin responses after intradermal injection of saline or exsheathed L3 H. contortus larvae (xL3). A: temperature of the injected
skin sites measured 2 h after intradermal injection of saline (S) or xL3 (L). B: wheal responses measured 2 h or 48 h after intradermal injection of xL3.
C: Number of eosinophils/mm2 tissue section of xL3 injected sites. Dashed line delineates the upper 95% confidence interval from the mean of the
combined saline injected sites. For details of experimental groups, refer to Table 1. Asterisk denotes significance levels at p,0.05 (*), p,0.01 (**) or
p,0.001 (***).
doi:10.1371/journal.pone.0078357.g004
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L3 H. contortus larvae has been shown both in vitro [21] and in vivo
[22]. Surprisingly, eosinophil numbers were not increased but
slightly reduced in skin biopsies after injection with L3 in the
aluminium vaccinated sheep compared to the adjuvant control
group. Eosinophil numbers did however correlate strongly with
protection in the aluminium vaccine group, suggesting that they are
involved in larval killing as observed during natural infection
[20,22]. In vitro studies, have shown that activation of eosinophils is
required for effective killing [21] and this may occur in the
aluminium vaccinated but not in the control sheep. In addition, as
eosinophils in immune sheep are strongly attracted to the tissue
larvae [20,22], it is possible that cell counts of surrounding tissues
may not adequately reflect the true level of eosinophil recruitment.
Quil A is a quintessential type-1 adjuvant currently incorporat-
ed into several veterinary vaccines [23]. In agreement with the
type-2 hypothesis above and its known downregulation by type-1
cytokines, any protection observed in the aluminium adjuvant
group was abrogated by the addition of Quil A to the vaccine.
Previous studies using pertussis toxin or Freund’s complete
adjuvant in the HcsL3 vaccine, while increasing the antibody
responses, have also resulted in a lack of protection or even
exacerbation of infection [8,24]. Together, these studies emphasise
the importance of choosing the right adjuvant for a particular
disease or a desired immune effector response.
DEAE-dextran (DD) is a high molecular weight positively
charged polymer that has received renewed interest as a vaccine
adjuvant due to its antibody enhancing properties in anti-fertility
vaccines [25]. The mode of action and the type of immune
response elicited with this adjuvant have however not been studied
in detail. In the present study, DD was the only adjuvant that
elicited a detectable increase in antigen-specific antibodies, and
these were significant for the IgG2 and IgE isotypes. In addition,
skin biopsied after i.d. L3 injection revealed a massive increase in
eosinophils, orders of magnitude above the control and aluminium
injected sheep, indicating a predominant type-2 immune response
induced by this adjuvant. Eosinophil numbers in skin biopsies
taken 48 h after i.d. L3 injection, did not however correlate with
protective immunity in this group, but were difficult to accurately
enumerate due to their large numbers and the presence of
numerous eosinophil-rich granulomas. Protection in the DD group
of sheep was significantly correlated with the 2 h wheal responses
suggesting that the protection observed in this group was manifest
at this early time period and eosinophil numbers at this time may
show correlation with protection. It is also possible that other cell
types such as neutrophils and monocytes may have been recruited
and contributed to protection and this requires further detailed
studies at the earlier time points.
The present study has confirmed the critical dependence of
effective vaccines against infections on the nature of the immune
response induced by a particular adjuvant system. For helminth
vaccines that are based on mimicking natural immunity against
invading larvae, this may involve the use of adjuvants that induce a
type-2 immune response, most likely involving eosinophil-mediated
killing. In contrast to most bacterial and viral vaccines where
protection is based on antibodies only, the present vaccine has
shown no correlation with antibody levels, but significant correla-
tions with cellular responses, in particular eosinophil recruitment
Figure 5. Eosinophil infiltration after intradermal injection of
saline or exsheathed L3 H. contortus larvae (xL3). Representative
H&E stained sections of skin tissue injected with saline (a) or xL3 (b) of
group 1,2&4 sheep. Group 3 sheep (Ag+DEAE-dextran) showed much
higher eosinophil infiltration (c) and occasional granulomas (d).
doi:10.1371/journal.pone.0078357.g005
Table 2. Correlations between parasitological and immunological parameters in control and vaccinated sheep.
Group1: AlPO4;
n =10
Group 2: Ag+AlPO4+QuilA;
n=10
Group 3: Ag+DEAE-
dextran n=10
Group 4: Ag
+AlPO n=10
All Groups
n=30/40
Correlations with cumulative faecal egg counts (cFEC)
cFEC vs. worm burden 0.78* (0.01) ND 0.66 (0.04) 0.78 (0.01) 0.77 (,0.001)
cFEC vs. PCV 20.68 (0.03) 20.60 (0.07) 20.76 (0.01) 20.83 (0.003) 20.74 (,0.001)
cFEC vs. IgE (wk 0) 20.048 (0.90) 20.57 (0.09) 20.09 (0.80) 20.09 (0.80) 20.40 (0.01)
cFEC vs. wheal (2 h) 20.003 (0.99) 0.22 (0.54) 20.82 (0.004) 0.032 (0.93) 20.13 (0.41)
cFEC vs. eos/mm2 (L3) 20.28 (0.46) 20.78 (0.02) 0.37 (0.34) 20.82 (0.01) 20.30 (0.13)
cFEC vs. temp change(saline/L3) 0.34 (0.34) 0.05 (0.90) 0.16 (0.66) 0.77 (0.01) 0.29 (0.07)
Correlations of antibody isotypes 1 week after 2nd vaccination (wk -3) and skin responses after i.d. injection of L3
wheal 2 h vs. IgE 0.08 (0.83) 0.38 (0.28) 0.28 (0.43) 0.32 (0.37) 0.22 (0.17)
wheal 2 h vs. IgG2 20.20 (0.58) 0.59 (0.07) 0.64 (0.047) 0.47 (0.17) 0.37 (0.02)
wheal 48 h vs. IgE 0.04 (0.90) 0.33 (0.35) 0.83 (0.003) 0.63 (0.067) 0.70 (,0.001)
wheal 48 h vs. IgG1 20.43 (0.22) 0.48 (0.16) 0.65 (0.04) 20.10 (0.80) 0.39 (0.01)
*Spearman rank correlation coefficient (P value); bold numbers indicate significance at P,0.05. ND: not done.
doi:10.1371/journal.pone.0078357.t002
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and/or activation. It is however likely that specific antibodies will
still be required for effective antibody-dependent cell mediated
killing of invading larvae [20]. In addition to the protection
observed previously with aluminium adjuvant, the results of this
study have also provided a more effective adjuvant system for
helminth vaccines and revealed significant correlates of vaccine-
induced protection.
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